Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2016

01-05-2016 | Original Paper

A Randomized Controlled Trial of Personalized Text Message Reminders to Promote Medication Adherence Among HIV-Positive Adolescents and Young Adults

Authors: Robert Garofalo, Lisa M. Kuhns, Anna Hotton, Amy Johnson, Abigail Muldoon, Dion Rice

Published in: AIDS and Behavior | Issue 5/2016

Login to get access

Abstract

HIV-positive adolescents and young adults often experience suboptimal medication adherence, yet few interventions to improve adherence in this group have shown evidence of efficacy. We conducted a randomized trial of a two-way, personalized daily text messaging intervention to improve adherence to antiretroviral therapy (ART) among N = 105 poorly adherent HIV-positive adolescents and young adults, ages 16–29. Adherence to ART was assessed via self-reported visual analogue scale (VAS; 0–100 %) at 3 and 6-months for mean adherence level and proportion ≥90 % adherent. The average effect estimate over the 6-month intervention period was significant for ≥90 % adherence (OR = 2.12, 95 % CI 1.01–4.45, p < .05) and maintained at 12-months (6 months post-intervention). Satisfaction scores for the intervention were very high. These results suggest both feasibility and initial efficacy of this approach. Given study limitations, additional testing of this intervention as part of a larger clinical trial with objective and/or clinical outcome measures of adherence is warranted.
Literature
1.
Centers for Disease Control and Prevention. HIV surveillance report, 2013. Atlanta: GA; 2013.
2.
Centers for Disease Control and Prevention. HIV surveillance report, 2011. Atlanta: GA; 2013.
3.
4.
Bangsberg. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMed
5.
Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PloS one. 2008;3(7):e2783–7.CrossRefPubMedPubMedCentral
6.
Feingold A, Rutstein R, Meislich D, Brown T, Rudy B. Protease inhibitor therapy in HIV-infected children. AIDS Patient Care STDS. 2000;14(11):589–93.CrossRefPubMed
7.
Flynn P, Rudy B, Douglas S, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J| Infect Dis. 2004;190(2):271–9.CrossRefPubMed
8.
Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15(16):2109–17.CrossRefPubMed
9.
Lafeuillade A, Tamalet C, Pellegrino P, De Micco P, Vignoli C, Quilichini R. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection. J Acquir Immune Defic Syndr. 1994;7(10):1028–33.PubMed
10.
McNabb J, Ross J, Abriola K, Turley C, Nightingale C, Nicolau D. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33(5):700–5.CrossRefPubMed
11.
Murphy D, Wilson C, Durako S, Muenz L, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27–40.CrossRefPubMed
12.
Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRefPubMed
13.
Rao D, Kekwaletswe T, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28–33.CrossRefPubMed
14.
Belzer M, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health. 1999;25:316–9.CrossRefPubMed
15.
16.
Martinez J, Bell D, Camacho R, Henry-Reid LM, Bell M, Watson C, et al. Adherence to antiviral drug regimens in HIV-infected adolescent patients engaged in care in a comprehensive adolescent and young adult clinic. J Natl Med Assoc. 2000;92(2):55–61.PubMedPubMedCentral
17.
M urphy D, Belzer M, Durako S, Moussa S, Wilson C, Muenz L. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2005;159(8):764–70.CrossRef
18.
Naar-King S, Templin T, Wright K, Frey M, Parsons J, Lam P. Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care STDs. 2006;20(1):44–7.CrossRefPubMed
19.
Rogers AS, Miller S, Murphy D, Tanney M, Fortune T. The TREAT (therapeutic regimens enhancing adherence in teens) program: theory and preliminary results. J Adolesc Health. 2001;29S:30–8.CrossRef
20.
Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.CrossRefPubMed
21.
Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17(1):14–25.PubMedPubMedCentral
22.
MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. 2013;17(1):86–93.CrossRefPubMedPubMedCentral
23.
Woods S, Dawson MS, Weber E, Gibson S, Grant I, Atkinson JH. HIV Neurobehavioral Research Center Group, timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc. 2009;15:42–52.CrossRefPubMedPubMedCentral
24.
Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med. 2009;36(2):165–73.CrossRefPubMed
25.
Pew Research Center. Mobile technology fact sheet. Washington, DC: Pew Internet and American Life Project; 2014.
26.
Pew Research Center. Teens and technology. Washington, DC: Pew Research Center; 2013.
27.
Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLoS ONE. 2014;9(2):e88166.CrossRefPubMedPubMedCentral
28.
Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012;3:CD009756.PubMed
29.
Mbuagbaw L, van der Kop ML, Lester RT, Thirumurthy H, Pop-Eleches C, Ye C, et al. Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials. BMJ open. 2013;3(12):e003950.CrossRefPubMedPubMedCentral
30.
Dowshen N, Kuhns LM, Johnson A, Holoyda BJ, Garofalo R. Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders. J Med Internet Res. 2012;14(2):e51.CrossRefPubMedPubMedCentral
31.
32.
33.
Macdonell K, Naar-King S, Murphy DA, Parsons JT, Harper GW. Predictors of medication adherence in high risk youth of color living with HIV. J Pediatr Psychol. 2010;35(6):593–601.CrossRefPubMedPubMedCentral
34.
BioCreations. HIV drug resistance and the importance of adherence. Johns Hopkins School of Medicine Division of Infectious Diseases; 2008.
35.
Dowshen N, Kuhns LM, Gray C, Lee S, Garofalo R. Feasibility of interactive text message response (ITR) as a novel, real-time measure of adherence to antiretroviral therapy for HIV+ Youth. AIDS Behav. 2013;17(6):2237–43.CrossRefPubMed
36.
Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, Kahana SY, et al. The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial. AIDS Behav. 2014;18(4):686–96.CrossRefPubMedPubMedCentral
37.
Erlen JA, Cha ES, Kim KH, Caruthers D, Sereika SM. The HIV medication taking self-efficacy scale: psychometric evaluation. J Adv Nurs. 2010;66(11):2560–72.CrossRefPubMedPubMedCentral
38.
Tucker CM, Peterson S, Herman KC, Fennell RS, et al. Self-regulation predictors of medication adherence among ethnically different pediatric patients with renal transplants. J Pediatr Psychol. 2001;26(8):455–64.CrossRefPubMed
39.
Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health. 2007;40(1):96–8.CrossRefPubMedPubMedCentral
40.
Derogatis L. Brief symptom inventory: administration, scoring, and procedures manual. Minneapolis, MN: National Computer Systems, Inc.; 1993.
41.
Humeniuk R. Validation of the alcohol, smoking and substance involvement screening test (ASSIST) and pilot brief intervention: a technical report of phase II findings of the WHO ASSIST project. Geneva: World Health Organization; 2006.
42.
Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Progr Plan. 1979;2:197–207.CrossRef
43.
MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83–104.CrossRefPubMedPubMedCentral
44.
45.
Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879–91.CrossRefPubMed
46.
Selig JP, Preacher KJ. Mediation models for longitudinal data in developmental research. Res Hum Dev. 2009;6:144–64.CrossRef
47.
Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.CrossRefPubMedPubMedCentral
48.
Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database of System Rev. 2011;12:CD009513.
Metadata
Title
A Randomized Controlled Trial of Personalized Text Message Reminders to Promote Medication Adherence Among HIV-Positive Adolescents and Young Adults
Authors
Robert Garofalo
Lisa M. Kuhns
Anna Hotton
Amy Johnson
Abigail Muldoon
Dion Rice
Publication date
01-05-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1192-x

Other articles of this Issue 5/2016

AIDS and Behavior 5/2016 Go to the issue

Original Paper

Community-Based Accompaniment Mitigates Predictors of Negative Outcomes for Adults on Antiretroviral Therapy in Rural Rwanda

Substantive Review

Identifying Best Practices for Increasing Linkage to, Retention, and Re-engagement in HIV Medical Care: Findings from a Systematic Review, 1996–2014

Original Paper

Late Diagnosis of HIV Infection in Metropolitan Areas of the United States and Puerto Rico

Original Paper

Navigating Barriers to Vocational Rehabilitation for HIV-Positive Persons

Original Paper

Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients?

Original Paper

Improving Adherence to Care Among “Hard to Reach” HIV-Infected Patients in Argentina
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits